7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethylsulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine → HCID 86624190, Verbindung
Reaktionsgleichung
[Cl:1][C:2]1[CH:18]=[CH:17][C:5]2[CH2:6][CH2:7][N:8]([C:11](=[O:16])[C:12]([F:15])([F:14])[F:13])[CH2:9][CH2:10][C:4]=2[C:3]=1OS(C(F)(F)F)(=O)=O.[CH:27]1([CH2:30][NH:31][C:32]2[N:37]=[CH:36][N:35]=[C:34]([C:38]3[CH:45]=[CH:44][C:41]([CH2:42][NH2:43])=[CH:40][CH:39]=3)[CH:33]=2)[CH2:29][CH2:28]1>>[Cl:1][C:2]1[CH:18]=[CH:17][C:5]2[CH2:6][CH2:7][N:8]([C:11](=[O:16])[C:12]([F:15])([F:14])[F:13])[CH2:9][CH2:10][C:4]=2[C:3]=1[NH:43][CH2:42][C:41]1[CH:40]=[CH:39][C:38]([C:34]2[CH:33]=[C:32]([NH:31][CH2:30][CH:27]3[CH2:29][CH2:28]3)[N:37]=[CH:36][N:35]=2)=[CH:45][CH:44]=1Komponenten
3
Versuchsvorschrift
Use a method similar to the General Procedure 1-3, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (260 mg, 0.6 mmol) and 4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamine (300 mg, 1.18 mmol), to give 7-chloro-6-{4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an off-white foam (250 mg, 78%). MS (ES+) m/z: 530 (M+H)+.